The first in-human trial for the vaccine candidate, Ad26.COV2.S, is currently taking place in the U.S. and Belgium. Johnson & Johnson used its AdVac technology to develop Ad26.COV2.S, which was also used to develop its Ebola, HIV, RSV and Zika vaccine candidates.
Pending positive trial results, Johnson & Johnson plans to manufacture more than 1 billion doses throughout 2021. The U.S. has the option to buy another 200 million doses of Ad26.COV2.S later on.
More articles on pharmacy:
3 retail pharma giants disclose data breaches from break-ins: What to know
Amazon’s PillPack partners with New Jersey insurer, Prime Therapeutics
American women more likely than men to skip medication due to cost, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
